<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001835458</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001730430</issuerCik>
      <issuerName>Kiniksa Pharmaceuticals International, plc</issuerName>
      <secFileNumber>001-38492</secFileNumber>
      <issuerAddress>
        <com:street1>23 OLD BOND STREET, FLOOR 3</com:street1>
        <com:city>LONDON</com:city>
        <com:stateOrCountry>X0</com:stateOrCountry>
        <com:zipCode>WIS 4PZ</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>7814319100</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Ragosa Mark</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Officer</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Class A ordinary shares</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Charles Schwab &amp; Co., Inc.</name>
        <address>
          <com:street1>3000 Schwab Way</com:street1>
          <com:city>Westlake</com:city>
          <com:stateOrCountry>TX</com:stateOrCountry>
          <com:zipCode>76262</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>20000</noOfUnitsSold>
      <aggregateMarketValue>820000.00</aggregateMarketValue>
      <noOfUnitsOutstanding>43472928</noOfUnitsOutstanding>
      <approxSaleDate>10/28/2025</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Class A ordinary shares</securitiesClassTitle>
      <acquiredDate>10/28/2025</acquiredDate>
      <natureOfAcquisitionTransaction>Employee Stock Option Exercise</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Kiniksa Pharmaceuticals, Ltd.</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>20000</amountOfSecuritiesAcquired>
      <paymentDate>10/28/2025</paymentDate>
      <natureOfPayment>Broker Payment for Cashless Exercise</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Mark Ragosa</name>
        <address>
          <com:street1>3 OLD BOND STREET, FLOOR 3</com:street1>
          <com:city>LONDON</com:city>
          <com:stateOrCountry>X0</com:stateOrCountry>
          <com:zipCode>W1S 4PZ</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Kiniksa Pharmaceuticals International, plc</securitiesClassTitle>
      <saleDate>08/04/2025</saleDate>
      <amountOfSecuritiesSold>18889</amountOfSecuritiesSold>
      <grossProceeds>621259.00</grossProceeds>
    </securitiesSoldInPast3Months>
    <remarks>The options on this filing may be sold over various dates.</remarks>
    <noticeSignature>
      <noticeDate>10/28/2025</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>09/03/2024</planAdoptionDate>
      </planAdoptionDates>
      <signature>Mark Ragosa</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
